Shanghai Allist Pharmaceuticals Co., Ltd. in 1 story
The narratives 688578.SS currently appears in, with its side and exposure in each.
Bull side
1 story- China Becomes Pharma's Global R&D Engine
688578.SS in “China Becomes Pharma's Global R&D Engine”
FadingExposure: not rated yetWestern drugmakers are licensing clinically validated Chinese molecules rather than relying solely on expensive in-house discovery.
Allist's EGFR inhibitor furmonertinib has generated international development exposure through ArriVent, illustrating how Chinese clinical assets can be advanced globally by Western partners.
Bear side
0 storiesNo bear-side stories for 688578.SS yet.